Drug intelligence / Profile preview

cnm-znag

Development stage: Discontinued
Lead developer: Clene
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Oral, Topical

Overview

CNM-ZnAg is a proprietary zinc-silver ionic solution developed by Clene Nanomedicine. It has demonstrated both antiviral and antibacterial (antimicrobial) activity in preclinical and clinical studies. The drug is being investigated primarily for the treatment of infectious diseases, with a focus on COVID-19, where it has reached Phase 2 clinical trials. Its mechanism of action involves leveraging the antimicrobial properties of zinc and silver ions to inhibit viral and bacterial pathogens[1][2][5]. The product is formulated as an aqueous solution intended for oral administration in symptomatic patients[5]. No significant safety concerns have been reported in clinical studies to date[4].

Other names: CNM-ZnAG

Targets

Microbial nucleic acid

Beyond the preview

Go deeper on cnm-znag.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cnm-znag.

Explore the full profile